{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-007971","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.890165+00:00","generated_at":"2026-05-16T11:08:29.307956+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arrowhead prices upsized $625M zero-coupon convertible notes and $216.6M equity offering","bullets":["Net proceeds of ~$681.3M from $700M (including over-allotment) of 0.00% convertible notes due 2032.","Net proceeds of ~$216.6M from equity offering: 3.1M shares at $64.50 plus pre-funded warrants for 1.55M shares.","Notes convertible at initial price of ~$87.07 (35% premium); capped call transactions entered to reduce dilution.","Proceeds for general corporate purposes, R&D, commercialization, and potential prepayment of Sixth Street credit facility.","Offerings priced Jan 7, 2026; equity closes Jan 9, notes close Jan 12, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-007971","json":"https://secwatch.observer/filing/0001193125-26-007971.json","markdown":"https://secwatch.observer/filing/0001193125-26-007971.md","text":"https://secwatch.observer/filing/0001193125-26-007971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000119312526007971/0001193125-26-007971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000119312526007971/d94918d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:08:29.307956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25174d686664e740f8a025c8fe6fef70e6bbd739","claim":"ARROWHEAD PHARMACEUTICALS, INC. entered into Equity Underwriting Agreement with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters (effective 2026-01-07).","evidence_excerpt":"On January 7, 2026, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein (collectively, the “Equity Underwriters”), to issue and sell 3,100,776 shares of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000119312526007971/0001193125-26-007971-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters"},{"label":"Effective","value":"2026-01-07"}],"fact_type":"material_agreement"},{"claim_id":"67261f2736dd9f9907088167a8b1f8bb36bb2e78","claim":"ARROWHEAD PHARMACEUTICALS, INC. entered into Convertible Notes Underwriting Agreement with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters valued at $625,000,000 aggregate principal amount (effective 2026-01-07).","evidence_excerpt":"On January 7, 2026, the Company entered into an underwriting agreement (the “Convertible Notes Underwriting Agreement”) with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein (the “Convertible Notes Underwriters”), to issue and sell (the “Convertible Notes Offering”) $625,000,000 aggregate principal amount of its 0.00% convertible senior notes due 2032","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000119312526007971/0001193125-26-007971-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters"},{"label":"Value","value":"$625,000,000 aggregate principal amount"},{"label":"Effective","value":"2026-01-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}